Comparative Pharmacokinetics Study of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil Substance and its Solid Dispersion Systems on Rabbits

• Main Authors: V. M. Kosman, D. V. Demchenko, E. A. Jain (Korsakova), V. G. Makarov, V. Yu. Balabanyan
• Format: Article
• Language: Russian
• Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2021-05-01
• Series: Разработка и регистрация лекарственных средств
• Subjects: 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil; pharmaceutical substance; solid dispersions; oral application; pharmacokinetics; plasma; rabbits; hplc-uv
• Online Access: https://www.pharmjournal.ru/jour/article/view/889

Introduction. The study of pharmacokinetics of medicinal substances and evaluation of their pharmacokinetic parameters is a necessary stage of pharmaceutical development of original medicinal agents, allowing to choose the composition and dosage form of the preparation. This is due to obtaining characteristics of all processes that occur in the body of an animal (human), from the absorption of a drug from the place of administration to its excretion from the body.Aim. To conduct a study of the pharmacokinetics of the pharmaceutical substance and the complex compounds based on it to confirm the pharmaceutical development of a drug of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil and to justify the optimal composition of the ready dosage form (GLP).Materials and methods. The study was carried out on male rabbits with a single oral administration of investigated objects in one dose. Plasma concentrations of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil were determined by high performance liquid chromatography (HPLC) with ultraviolet (UV) detection. Pharmacokinetic parameters were calculated by extramodel method of statistical moments.Results and discussion. Assay 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil quantification in rabbit blood plasma by HPLC has been developed and validated in the concentration range 10–720 ng/ml in accordance with modern requirements and satisfies them for all indicators. Assay was applicated to analysis of plasma samples obtained from laboratory animals after a single oral administration of a substance and solid dispersion systems of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil in one dose. The main pharmacokinetic parameters of the studied objects were calculated after obtained plasma concentrations of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil. It was found that the solid dispersion system with Kollidon 17PF has the greatest relative bioavailability from the examined objects; its relative bioavailability to the substance by oral administration was 583 %.Conclusion. The solid dispersion system method increased the bioavailability of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil. Obtained results confirmed correctness of solid dispersion system selection drug e composition and technology development.